This site is only for patients in the UK who have been prescribed SOTYKTU^® (deucravacitinib)

Have you been prescribed SOTYKTU?

Yes No

Please read the Patient Information Leaflet (PIL) before taking SOTYKTU.

V This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

This page was last revised 04/2025 | Bristol-Myers Squibb Pharma EEIG PLGB 15105/0179

Back to top

Privacy Policy Legal Notice

1787-GB-2500003 | April 2025

This page was last revised 04/2025
Bristol-Myers Squibb Pharma EEIG PLGB 15105/0179

This site is only for patients in the UK who have been prescribed SOTYKTU® (deucravacitinib)

This site is only for patients in the UK who have been prescribed SOTYKTU^® (deucravacitinib)